<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00247208</url>
  </required_header>
  <id_info>
    <org_study_id>VISN 17, 10N17</org_study_id>
    <nct_id>NCT00247208</nct_id>
  </id_info>
  <brief_title>The SOS (Stenting Of Saphenous Vein Grafts) Trial</brief_title>
  <official_title>The SOS (Stenting Of Saphenous Vein Grafts) Randomized-controlled Trial of a Paclitaxel-eluting Stent vs. a Bare Metal Stent in Saphenous Vein Graft Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Texas Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clark R. Gregg Fund, Harris Methodist Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael Debakey Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Arizona VA Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onassis Cardiac Surgery Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>North Texas Veterans Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine whether implantation of a paclitaxel-eluting
      stent (Taxus™) in saphenous vein graft lesions will reduce the incidence of in-stent
      restenosis after 12 months when compared to a similar bare metal stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: The prevalence of coronary artery bypass graft (CABG) surgery is high in the
      veteran population. Saphenous veins are used as conduits in the majority of CABG operations.
      Compared to arterial conduits, saphenous vein grafts (SVGs) have a high rate of failure,
      requiring percutaneous coronary intervention (PCI) or repeat CABG. Bare metal stents are
      currently used in the majority of PCI in SVGs because they increase the procedural success
      rate and decrease restenosis. However, even with the use of bare metal stents, restenosis
      still occurs in 37-53% of the SVGs, often requiring repeat target vein graft
      revascularization.

      Drug-eluting stents (DES) have been a major breakthrough in percutaneous coronary
      intervention because they significantly reduce the incidence of in-stent restenosis in de
      novo lesions of native coronary arteries. Even though, no randomized controlled trials have
      compared DES with bare stents in SVG interventions, DES are increasingly being used off label
      in this setting, based on registry data. DES are expensive and may not provide benefit in
      SVGs since the atherosclerotic process is different in SVGs and in native coronary arteries.
      We propose to compare the 12-month angiographic restenosis rates after implantation of a
      polymer-based paclitaxel-eluting stent or the Express-2 bare metal stent (which is identical
      to the paclitaxel-eluting stent but has no drug coating) in saphenous vein graft lesions.

      Hypothesis: Compared to implantation of a bare metal stent, implantation of a similar
      paclitaxel-eluting stent (Taxus™, Boston Scientific, Nattick, Massachusetts) in saphenous
      vein graft lesion will reduce the incidence of angiographic in-stent restenosis after 12
      months.

      Specific objectives: We propose to randomize patients undergoing stenting of a saphenous vein
      graft lesion to a bare metal stent or an identical paclitaxel-eluting stent (Taxus™) in order
      to determine:

        1. whether the paclitaxel-eluting stent will reduce the incidence of binary angiographic
           in-stent restenosis, as assessed by 12-month follow-up quantitative coronary angiography
           (primary study endpoint), and

        2. whether the paclitaxel-eluting stent will reduce the 24-month incidence of
           ischemia-driven target vessel revascularization, target vessel failure, overall major
           adverse cardiac and cerebrovascular events, and intra-stent intimal hyperplasia
           accumulation, as measured by intravascular ultrasound (secondary endpoints).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>binary angiographic in-stent restenosis, as assessed by 12-month follow-up quantitative coronary angiography</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>intrastent intimal hyperplasia accumulation as measured by IVUS</measure>
    <time_frame>12 months for IVUS and 24 months for clinical follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of ischemia-driven target vessel revascularization, target vessel failure, and overall major adverse cardiac and cerebrovascular events at 24-month follow-up</measure>
    <time_frame>12 months for IVUS and 24 months for clinical follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Coronary Artery Bypass</condition>
  <condition>Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Express 2 bare metal stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taxus, paclitaxel-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus polymer-based paclitaxel-eluting stent</intervention_name>
    <description>Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Taxus drug-eluting stents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Express 2 bare metal stent</intervention_name>
    <description>Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least one 50-99% de-novo or restenotic lesion in a saphenous vein graft that is
             between 2.5 and 4.0 mm in diameter, requiring percutaneous coronary intervention
             according to the opinion of the attending cardiologist

          -  willing to return for repeat coronary angiography after 12 months

          -  able to give informed consent

        Exclusion Criteria:

          -  previous or planned use of intravascular brachytherapy in the target vessel

          -  a left ventricular ejection fraction of less than 25 percent

          -  hemorrhagic diatheses

          -  contraindications or allergy to aspirin, thienopyridines, paclitaxel, or stainless
             steel

          -  a history of anaphylaxis in response to iodinated contrast medium

          -  use of paclitaxel within 12 months before study entry or current use of colchicine

          -  a serum creatinine level of more than 2.0 mg per deciliter (177 µmol per liter)

          -  a leukocyte count of less than 3500 per cubic millimeter, or a platelet count of less
             than 100,000 per cubic millimeter

          -  a recent positive pregnancy test, breast-feeding, or the possibility of a future
             pregnancy

          -  coexisting conditions that limit life expectancy to less than 24 months or that could
             affect a patient's compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanouil S Brilakis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA North Texas Health Care System, University of Texas Southwestern Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Iowa City Healthcare system</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. Debakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onassis Cardiac Surgery Center</name>
      <address>
        <city>Athens</city>
        <zip>17674</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.northtexas.va.gov/research/SOS/index.asp</url>
    <description>Trial main website</description>
  </link>
  <results_reference>
    <citation>Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol. 2009 Mar 17;53(11):919-28. doi: 10.1016/j.jacc.2008.11.029.</citation>
    <PMID>19281920</PMID>
  </results_reference>
  <results_reference>
    <citation>Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, Haagen D, Saeed B, Iturbe JM, Shunk K, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. JACC Cardiovasc Interv. 2009 Sep;2(9):855-60. doi: 10.1016/j.jcin.2009.06.014.</citation>
    <PMID>19778774</PMID>
  </results_reference>
  <results_reference>
    <citation>Michael TT, Abdel-karim AR, Papayannis A, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, Brilakis ES. Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial. J Invasive Cardiol. 2011 Jun;23(6):216-9.</citation>
    <PMID>21646644</PMID>
  </results_reference>
  <results_reference>
    <citation>Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv. 2011 Feb;4(2):176-82. doi: 10.1016/j.jcin.2010.10.003.</citation>
    <PMID>21349456</PMID>
  </results_reference>
  <results_reference>
    <citation>Michael TT, Badhey N, Banerjee S, Brilakis ES. Comparison of characteristics and outcomes of patients undergoing saphenous vein graft stenting who were or were not enrolled in the stenting of saphenous vein grafts randomized controlled trial. J Investig Med. 2011 Feb;59(2):259-66. doi: 10.231/JIM.0b013e318207066c.</citation>
    <PMID>21200334</PMID>
  </results_reference>
  <results_reference>
    <citation>Badhey N, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Addo TA, Haagen D, Abdel-Karim AR, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, Brilakis ES. Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv. 2010 Aug 1;76(2):263-9. doi: 10.1002/ccd.22438.</citation>
    <PMID>20665875</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2005</study_first_submitted>
  <study_first_submitted_qc>October 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2005</study_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Texas Veterans Healthcare System</investigator_affiliation>
    <investigator_full_name>Emmanouil Brilakis</investigator_full_name>
    <investigator_title>Director, Cardiac Catheterization Laboratories, VA North Texas Healthcare System</investigator_title>
  </responsible_party>
  <keyword>Coronary artery bypass</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty, Transluminal, Percutaneous Coronary</keyword>
  <keyword>Coronary Restenosis</keyword>
  <keyword>Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

